Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Interviews

Interview
UC Davis Vascular Center Spotlight with Professor David L. Dawson, MD
07/06/2011
The UC Davis Vascular Center provides total vascular care. Ours is a multidisciplinary center, integrating the services of all specialists and subspecialists involved in diagnosing and treating any form of blood-vessel disease—from varicose...
The UC Davis Vascular Center provides total vascular care. Ours is a multidisciplinary center, integrating the services of all specialists and subspecialists involved in diagnosing and treating any form of blood-vessel disease—from varicose...
The UC Davis Vascular Center...
07/06/2011
Vascular Disease Management
Interview
Vascular Practice Development Q&A with Gary M. Ansel, MD
06/02/2011
Today’s market will be expanded by the increase in outcome data being generated. The 2 major trials that I predict will increase the market are the CREST data that show similar outcomes to caroti­­­d endarterectomy overall while...
Today’s market will be expanded by the increase in outcome data being generated. The 2 major trials that I predict will increase the market are the CREST data that show similar outcomes to caroti­­­d endarterectomy overall while...
Today’s market will be expanded...
06/02/2011
Vascular Disease Management
Interview
VDM speaks with Marco G. Manzi, MD, Chief of the Interventional Radiology Unit in Policlinico Abano Terme (Vincenza, Italy), who presented on "Saving the Limb in Diabetics with Disease of the Leg or Foot" at the 37th Annual VEITHSymposium
05/03/2011
Tell us where things stand presently with treatment options for diabetics with critical limb ischemia.
Tell us where things stand presently with treatment options for diabetics with critical limb ischemia.
Tell us where things stand...
05/03/2011
Vascular Disease Management
Interview
Vascular Practice Development Q&A with James F. Benenati, MD
05/03/2011
Peripheral arterial disease (PAD) is still not well recognized in the community and not well understood by many primary care physicians. There is a huge untapped market and many of these patients need help.
Peripheral arterial disease (PAD) is still not well recognized in the community and not well understood by many primary care physicians. There is a huge untapped market and many of these patients need help.
Peripheral arterial disease...
05/03/2011
Vascular Disease Management
Interview
VDM Speaks with Scott E. Kasner, MD, MSCE
03/31/2011

Scott E. Kasner, MD

Scott E. Kasner, MD
What do we know thus far from the clinical trials about the efficacy and safety of patent foramen ovale (PFO) closure for cryptogenic stroke?
What do we know thus far from the clinical trials about the efficacy and safety of patent foramen ovale (PFO) closure for cryptogenic stroke?
What do we know thus far from...
03/31/2011
Vascular Disease Management
Interview
VDM Speaks with Jes S. Lindholt, MD, DMSci, PhD, Principal Investigator, Scandinavian PROPATEN Clinical Trial
03/31/2011
Tell us about the findings of the Scandinavian clinical trial involving the GORE® PROPATEN® heparin-bonded vascular graft for the treatment of lower-limb ischemia.
Tell us about the findings of the Scandinavian clinical trial involving the GORE® PROPATEN® heparin-bonded vascular graft for the treatment of lower-limb ischemia.
Tell us about the findings of...
03/31/2011
Vascular Disease Management
Interview
VDM Speaks with Peter J. Pappas, MD, FACS, President of the American Venous Forum
03/08/2011
Why has venous disease been understudied compared to other types of disease?
Why has venous disease been understudied compared to other types of disease?
Why has venous disease been...
03/08/2011
Vascular Disease Management
Interview
VDM Speaks with Walter Dorigo, MD, about Limb Salvage in Diabetics with CLI Using the Gore Propaten Heparin-Bonded ePTFE Vascular Graft
03/08/2011
What do the study data show thus far regarding treatment of infrainguinal critical limb ischemia using the heparin-bonded ePTFE vascular graft?
What do the study data show thus far regarding treatment of infrainguinal critical limb ischemia using the heparin-bonded ePTFE vascular graft?
What do the study data show thus...
03/08/2011
Vascular Disease Management
Interview
VDM Speaks with Dr. Tod C. Engelhardt About Ultrasonic-Enhanced Thrombolysis for PE
03/08/2011
Dr. Tod C. Engelhardt, Chairman of the Cardiovascular and Thoracic Surgery Division of East Jefferson General Hospital in Metairie, Louisiana, spoke with VDM following his presentation on ultrasonic-enhanced thrombolysis for pulmonary...
Dr. Tod C. Engelhardt, Chairman of the Cardiovascular and Thoracic Surgery Division of East Jefferson General Hospital in Metairie, Louisiana, spoke with VDM following his presentation on ultrasonic-enhanced thrombolysis for pulmonary...
Dr. Tod C. Engelhardt, Chairman...
03/08/2011
Vascular Disease Management
Interview
VDM Speaks with Dr. Clem Darling about the AAA Awareness Campaign Making National Headlines
02/02/2011
What is the “Find the AAAnswers Coalition”?
What is the “Find the AAAnswers Coalition”?
What is the “Find the AAAnswers...
02/02/2011
Vascular Disease Management

Advertisement

Advertisement

Stay in the Know

Vascular Disease Management Newsletter

Advertisement

Advertisement

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement